Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company focused on central nervous system (CNS) and immunology treatments, announced its management team will participate in two upcoming investor conferences in May 2026. The company will attend the RBC Capital Markets Global Healthcare Conference on May 19 in New York and A.G.P.’s Annual Virtual Healthcare Conference on May 20. These events provide platforms for Tonix to update the investment community on its recent milestones and strategic direction.
Tonix recently received FDA approval for TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The company is now building its CNS commercial infrastructure to support TONMYA, along with its existing acute migraine products, Zembrace® SymTouch® and Tosymra®. Beyond fibromyalgia, Tonix is exploring TONMYA’s potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder. The company’s CNS pipeline also includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare disease with high unmet need.
In immunology, Tonix is advancing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection. These programs underscore Tonix’s commitment to addressing serious conditions through innovative science. The investor conferences offer an opportunity for management to discuss these developments and the company’s strategy for growth.
For more details, the full press release is available at https://ibn.fm/ZZpG2. Additional updates on TNXP can be found in the company’s newsroom at https://ibn.fm/TNXP.
The participation in these conferences signals Tonix’s proactive engagement with the investment community as it transitions from a development-stage to a commercial-stage company. With TONMYA’s approval and a robust pipeline, Tonix is positioned to address significant gaps in CNS and immunology treatments. Investors and analysts will closely follow the company’s progress as it seeks to expand its commercial footprint and advance its clinical programs.
